---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-039106"
form_type: "8-K"
ticker: "RAPH"
cik: "0001415397"
company_name: "Raphael Pharmaceutical Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:15:08.848874+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Raphael Pharma launches US proof-of-concept CBG trial for rheumatoid arthritis

## Summary
- Proof-of-concept clinical trial begun in US for Cannabigerol (CBG) in active Rheumatoid Arthritis patients.
- Engaged MindMate/Citruslabs to oversee trial; estimated timeline 6 months from first participant recruitment.
- Trial leverages pre-clinical experiments conducted at Rambam Health Care Campus, Israel.
- No financial guidance or material financial impact disclosed in filing.

## SEC filing metadata
- accession: 0001213900-24-039106
- form_type: 8-K
- ticker: RAPH
- cik: 0001415397
- company_name: Raphael Pharmaceutical Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1415397/000121390024039106/0001213900-24-039106-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1415397/000121390024039106/ea0205172-8k_raphael.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-039106
- JSON: https://secwatch.observer/filing/0001213900-24-039106.json
- Plain text: https://secwatch.observer/filing/0001213900-24-039106.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.